| Literature DB >> 34546336 |
Jakob Kreye1,2,3,4,5, Sukhvir K Wright6,7, Adriana van Casteren1, Laura Stöffler1,3, Marie-Luise Machule1,3, S Momsen Reincke1,2,3,5, Marc Nikolaus4,7,8, Scott van Hoof1,2,3, Elisa Sanchez-Sendin1,2,3, Marie A Homeyer1,3, César Cordero Gómez1,3, Hans-Christian Kornau1,9, Dietmar Schmitz1,9, Angela M Kaindl4,8,10, Philipp Boehm-Sturm3,9, Susanne Mueller3,9, Max A Wilson6, Manoj A Upadhya6, Divya R Dhangar6, Stuart Greenhill6, Gavin Woodhall6, Paul Turko11, Imre Vida11, Craig C Garner1, Jonathan Wickel12, Christian Geis12, Yuko Fukata13,14, Masaki Fukata13,14, Harald Prüss1,2,3.
Abstract
Autoantibodies targeting the GABAA receptor (GABAAR) hallmark an autoimmune encephalitis presenting with frequent seizures and psychomotor abnormalities. Their pathogenic role is still not well-defined, given the common overlap with further autoantibodies and the lack of patient-derived mAbs. Five GABAAR mAbs from cerebrospinal fluid cells bound to various epitopes involving the α1 and γ2 receptor subunits, with variable binding strength and partial competition. mAbs selectively reduced GABAergic currents in neuronal cultures without causing receptor internalization. Cerebroventricular infusion of GABAAR mAbs and Fab fragments into rodents induced a severe phenotype with seizures and increased mortality, reminiscent of encephalitis patients' symptoms. Our results demonstrate direct pathogenicity of autoantibodies on GABAARs independent of Fc-mediated effector functions and provide an animal model for GABAAR encephalitis. They further provide the scientific rationale for clinical treatments using antibody depletion and can serve as tools for the development of antibody-selective immunotherapies.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34546336 PMCID: PMC8480667 DOI: 10.1084/jem.20210012
Source DB: PubMed Journal: J Exp Med ISSN: 0022-1007 Impact factor: 14.307